Soy, a major component of the diet for centuries contains the largest concentration of isoflavones, a class of phytoestrogens. A variety of health benefits are associated with the consumption of soy primarily because of the isoflavones genistein, daidzein, and glycitein with a potential protective effect against a number of chronic diseases. Owing to the pharmaceutical and nutraceutical properties allied with isoflavonoids and their use in functional foods, there is a growing interest in these compounds. This review throws light on the chemistry, and significant pharmacological and biopharmaceutical aspects of soy isoflavones. This article critically describes the mechanisms of action, infers conclusions and shows opportunity for future research.
Introduction
Dietary intake of plant-based foods has been known to reduce morbidity and mortality of many chronic diseases. Over the recent decades, researchers have developed an interest in the health benefits of soy products. Soybeans, apart from being high in protein content, are also known as a rich source of isoflavones [1] [2] [3] , providing clinical nutrition on account of their large spectrum of hormonal and non-hormonal activities. Recent interest in them has been encouraged by the potential health benefits including anticarcinogenic [4] , antiangiogenic [5] and antioxidative [6] . Further studies show that a diet rich in isoflavones is associated with diminished risk of cancers, osteoporosis and cardiovascular disease [7, 8] .
Soy isoflavone activities are structurally dependent. They are nonsteroidal heterocyclic phenols with structural similarity to estradiol-17-beta and selective estrogen receptor modulators and show marked estrogenic and anti-estrogenic activities. Amongst the important phytochemicals in soybean, phytoestrogens, mainly the isoflavones genistein, daidzein and glycitein, have been most widely studied.
On account of the various pharmacological activities exhibited by isoflavones, to date, no review has provided an integrated view of the role of soy isoflavones with their mechanism of actions. Even though the mechanisms of isoflavones are still not completely known, evidence from the documented experimental studies proposes that they act in multiple ways, to exhibit various therapeutic effects.
The current review is a comprehensive summary of effects associated with changes in the chemical structure and variability in metabolism, coupled with mechanisms of action of soy isoflavones as indicated for clinical application in various treatment strategies for different diseases. It further aims to communicate the advances in scientific knowledge associated with soy isoflavones with the intention to simulate further research to optimize their delivery systems and beneficial effects.
Chemistry
Isoflavones, 3-phenyl-4H-1-benzopyran-4-ones, are the bioactive secondary metabolites mostly found in soy products [9] . Soy Chemical structure of isoflavones isoflavones consist of four chemical forms and each of which has three different types: the aglycones, daidzein, genistein, and glycitein; the glucosides, daidzin, genistin, and glycitin; the acetylglucosides, 6"-O-acetyldaidzin, 6"-O-acetylgenistin, and 6"-O-acetylglycitin; and the malonylglucosides 6"-O-malonyldaidzin, 6"-O-malonylgenistin, and 6"-O-malonylglycitin [10] . The basic skeleton of isoflavone consists of fused A-and C-rings connected to the B-ring through carbon 3 (C3). The functional group attached to this basic skeleton is mainly hydroxyl.
Structure activity relationship
The biological activities of isoflavones are based upon the configuration, total number of hydroxyl groups, and substitution of functional groups around their nuclear structure.
Arrangement of functional groups affects the antioxidant activity of isoflavones. The configuration, substitution, and total number of hydroxyl groups considerably influence several mechanisms of antioxidant activity such as radical scavenging and metal ion chelation ability [11] . Based on the xanthine/xanthine oxidase assay of isoflavones, it was concluded that the presence of a hydroxyl group at R7 position in ring A and a methoxy group at R4′ in ring B with either a hydroxyl group at R3′ or R5′ leads to high activity. However, R7-OH and R4′-OMe without any substituent possess low activity. The presence of R2′-OMe can reduce the positive effect of the R3′-OH or R5′-OH substitution. This shows that R3′-OH and R5′-OH, as well as non-methylated R′4-OH substitutions in the isoflavonoids strongly promote the superoxide radical scavenging activities whereas the R2′-OMe substitution reduces the superoxide radical scavenging effect [12] .
In another study, in ORAC [Oxygen Radical Absorbance Capacity] assay, it was suggested that R4′-OH substitution with either hydroxyl substitution at R3′ or R5′ and to a lesser extent R5 in the isoflavonoids promotes oxygen radical absorbance capacity, while the replacement of R4′-OH with -OMe significantly reduces the ORAC value [12] .
Regarding the estrogenic activity shown by these phytochemicals, it has been reported that hydroxyl substituents at position 4' and 7 are invariably estrogenic in nature, and an additional hydroxyl group in position 5 is not only tolerated but may in some cases increase the estrogenic potential of the compounds. Also, 4'-methoxylation of isoflavones reduces or eliminates the estrogenic activity of these compounds relative to their 4-hydroxy counterparts [14] .
Biological aspect
Anti-osteoporotic activity: Osteoporosis is a disorder associated with reduction in bone mass leading to brittle and fragile bones prone to sudden fractures and structural degradation of bone tissue. The imbalance between the osteoblast (bone building activity) and osteoclast (bone resorption activity) causes osteoporosis. Risk factors include hormonal imbalance, age, gender, and deficiency of calcium and vitamin D.
One of the major culprits of osteoporosis is a decreased estrogen level. Estrogen is a signaling molecule which binds to the estrogen receptors (present in bone, liver, heart and brain), forming a complex with DNA to alter the expression of estrogen-responsive genes.
Phytoestrogens are structurally similar to 17β-estradiol, consequently they bind to estrogen receptors α and β (preferably βestrogen receptor) and exhibit estrogenic activity. Genistein appears to be the most efficient isoflavone in protecting bone health. It is not only responsible for stimulating osteoblasts by suppressing bone breakdown, but also inhibits osteoclasts by increasing the expression of osteoprotegerin, which is an osteoclastogenic inhibitor responsible for neutralizing the effect of RANKL (receptor activator of nuclear factor-κB ligand) [15] .
The exact mechanism of action by which isoflavones preserve bone health is still not completely understood but it seems that they kindle the activity and proliferation of bone-building cells, known as osteoblasts, to maintain bone mass against the action of osteoclast cells (16) (17) (18) (19) (20) (21) . Many researchers have published reports of experimental studies on humans, animals, isolated cells, and tissues and have demonstrated that isoflavones (especially genistein) at appropriate doses improve bone density [22] . In a rat model of osteopenia, it was shown that soy protein increased the gene expression of IGF-I as indicated by higher femoral mRNA levels [23] . It was further observed that soy protein with normal isoflavone content (2.3 mg/g protein) had a greater effect on femoral IGF-I mRNA than the isoflavone-depleted soy proteinbased diet (approximately 0.1 mg/g protein) demonstrating the role of isoflavones in enhancing the synthesis of IGF-I at the bone level. Further, it has been well known that IGF-I stimulates osteoblastic activity in humans [24] and IGF-I concentrations have been reported to be associated positively with bone mass in pre- [25] , peri- [26] , and post- [27] menopausal women [28, 29] . Yang et al. recently reported the effect of soy isoflavones against retinoic acidinduced osteoporosis in Kunming mice [30] . Experimental findings suggest that soy isoflavones in ovariectomized rats reduce the urinary excretion of a specific marker of bone resorption i.e., deoxypyridinoline [Dpd] [16, 17] . Further, soy intake in Japanese postmenopausal women was related to lower urinary Dpd excretion [31] . In another study with postmenopausal women who were assigned to a soy milk regimen providing 60-70 mg of isoflavones, a considerable decrease was recorded in urinary N-terminal crosslinked peptides, which is another specific marker of bone resorption [17] . It has also been reported [32] that the daily consumption of 40 g soy protein, but not milk protein, for three months by postmenopausal women who were not on HRT significantly reduced the urinary excretion of Dpd. These studies illustrate that the intake of isoflavones is responsible for suppressed.
Genistein administration for six months in postmenopausal women led to a significant increase in bone density and concurrent reduction in the concentration of biochemical markers of bone resorption [33] . However, the mechanisms of isoflavones are still not clear, but data from studies recommend that they act in multiple ways to preserve bone mass.
Antioxidant activity:
The antioxidant property of isoflavones might be attributed to their phenolic structure, which upholds the redox balance of normal cells. As reported by Bouker et al. [34] , genistein has been shown to possess antioxidant properties. It has a potential antioxidant effect on producing hydrogen peroxide by 12-O-tetrade-canoylphorbol-13-acetate-activated HL-60 cells. Enhancement of the antioxidant activity of genistein in skin and small intestine of mice was observed by Amigo-Benavent's studies [35] . Liu et al. [36] showed that daidzein enhances catalase activity at 100 μmol/L in a reporter gene assay and in Northern blot experiments at 200 μmol/L. Stroke patients were given a soy cream product (10.6% protein) that reduced lipid peroxidation in molecules of low-density lipoprotein (LDL) cholesterol, very-lowdensity lipoprotein cholesterol, and high density lipoprotein cholesterol (HDL) [37] . Another report on genistein showed that it inhibits the oxidation of LDL cholesterol in the presence of either copper ions or superoxide/nitric acid radicals. Further, this indicated that human endothelial cells were efficiently protected by genistein from damage by oxidized lipoproteins [38, 39] .
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Natural Product Communications Vol. 12 (4) 2017 629 Antioxidant effects of isoflavones are mediated by their action on β estrogen receptors. Genistein binds specifically to the β-estrogen receptor, and decreases the basal peroxide levels in MCF-7 cells. Further, isoflavones induce ERK1/2 phosphorylation in MCF-7 cells and up-regulate the expression of the MnSOD gene. Therefore, the antioxidant effects of isoflavones are mediated via up-regulation of antioxidant gene expression, involving activation of ERK1/2 and NF k β [40] .
A study reports that gastric digestion influences the release of bioactive substances from the soymilk matrix, increasing the concentration of total phenolic (isoflavone) components to 22%, leading to total antioxidant activity (76%) [41] . Another report by Cai et al., on white sufu, showed an increase in antioxidant activity of isoflavones of 2.8 and 1.6 fold using the ferric reducing power (FRAP) and 2,2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid radical scavenging activity assays (ABTS RSA) [42] .
Anti-atherosclerotic activity:
Atherosclerosis is a disorder of the artery wall that might be attributed to environmental and genetic factors [43, 44] . Various animal and human studies have shown that soy isoflavones improve blood lipid levels and prevent atherosclerosis. There are numerous mechanisms which are responsible for preventing atherosclerosis and consequently CHD by the isoflavones. Isoflavones have been shown to activate estrogen receptors and enhance endothelial NO-synthase expression (eNOS), suppress oxidative stress, and increase NO availability [45] . Also, isoflavones are reported to alter several signaling pathways, including cAMP/protein kinase A, phosphatidylinositol-3-kinase (PI3-kinase)/protein kinase B (Akt), which further mediate initiation of heme oxygenase 1 (HO-1) and other antioxidant defense genes in oxidative stress, and extracellular signal-regulated kinase 1 and 2 (ERK 1/2), leading to enhanced eNOS activity and NO formation [46] [47] [48] .
Genistein also inhibits tyrosine kinase, so this might also account for the cardiovascular protection. Kanazawa et al. [49] report that soy cream suppressed the size of LDL particles and also soymilk preserved LDL from peroxidization. Genistein is also stated to reduce the proliferation and migration of smooth muscle cells [50, 51] , which are responsible for the development of atherosclerotic lesions. Genistein might also reduce thrombus formation by hindering platelet activation [52, 53] and aggregation [54, 55] . The atherosclerotic lesion area of the aortic arch was found to be significantly lower in the isoflavone groups (26.3% lower in the low isoflavone group and 36.9% lower in the high isoflavone group) than in the cholesterol group [56] . Another study documented that isoflavones containing a soy protein diet reduced VLDL (very low lipoprotein) and LDL (low density lipoprotein) cholesterol levels and reduced aortic sinus lesions in C57BL/6 mice compared with isoflavones free diet [57] . Besides this, soy isoflavones were shown to improve lipid profiles in Sprague Dawley rats with rheumatic arthritis [58] .
Another study on genistein fed C57BL/6 mice by Naaz et al. has shown decreased adipose deposition due to its action on estrogen receptor-α [59] . Thus the estrogen receptor played an important role in developing atherosclerosis. Further, the chemical structure of the isoflavones resemble those of fibrates, the agonists of peroxisome proliferator agonist receptor-α (PPARα) used to treat hyperlipidemia and type-2 diabetes. Thus, it is believed that the enhancements in liver lipid levels related with soy consumption might be due to PPAR activation by isoflavones as considered by Repa et al. [60] . Further, it was concluded by Dang et al. that genistein is a ligand for PPARγ [61] .
Anticancer activity:
The cancer protective effects of isoflavones have been attributed to a wide variety of signaling pathways, including cell cycle regulation, inhibition of cell proliferation, induction of apoptosis, inhibition of activation of nuclear factor kappa beta (NF-κB) and regulation of mitogen-activated protein kinase pathway (MAPK).
It has been documented by Casagrande et al. that genistein causes a G2/M cell cycle arrest in breast cancer, gastric adenocarcinoma and melanoma cells [62] . Cancer cells treated with different concentrations of genistein showed a dose-dependent decrease in the expression of cyclin B, which exhibits a significant role in the positive regulation of cyclin dependent kinase activity and is essential for composing cyclin B/CDK complex through the G2/M phase series. Thus, genistein stimulates G2/M cell cycle arrest in cancer cells by the down-regulation of cyclin B [63] .
Transforming growth factor β1 (TGFβ1) is responsible for stimulation as well as inhibition of cell proliferation in a cell-typespecific manner. It also attenuates passage through cell cycle checkpoints, which consecutively have a role in preventing the cells from entering G1/S transition [64] . By using enzyme linked immunosorbent (ELISA) assay with monospecific TGFβ1 antibodies in HME (human mammary epithelium) cells, genistein secreted nearly a 5-fold higher amount of TGFβ1, which depicts that genistein increases either the secretion or the synthesis from HME cells [65] .
Genistein administration has also been found to cause downregulation of B-cell lymphoma 2 (Bcl-2) protein expression and upregulation of Bcl2-associated X protein (Bax) expression, as well as activation of caspases that induce apoptosis in a variety of human cancer cells [66] .
Another study have demonstrated that genistein inhibits the translocation of NFκB to the nucleus preventing its binding to the target DNA, thereby suppressing the transcription of NFκB downstream genes [67] . This process eventually inhibits cell growth and also induces apoptotic cell death. In the NFκB signaling pathway, IκB (inhibitor of kappa B) is phosphorylated by IκB kinase-α (IκKα) and IκB kinase-β (IκKβ), while IκK is phosphorylated and activated by the upstream molecule, mitogen activated kinase kinase 1 (MEKK1) [68, 69] . Genistein has been shown to inhibit MEKK1 activity, resulting in the inactivation of NFκB due to decreased phosphorylation of IkB. Beside this, the Akt (protein kinase B) pathway also regulates the NFκB pathway via phosphorylation and activation of molecules [70] . Akt, also known as protein kinase B, is a serine/threonine-specific protein kinase, which plays a critical role in apoptosis. By various kinetic studies, it was found that the level of phosphorylated Akt protein at Ser473 was reduced by genistein in a dose dependent manner [71] . Hence, involvement of NFκB and Akt in the signaling pathway by genistein may be one of the molecular mechanisms by which it inhibits cancer cell growth and induces apoptosis.
Genistein also inhibits NFkβ by the MAPK pathway, which consists of a series of three kinases where MAP3K activates a MAP2K that further activates MAPK (ERK, JNK, and p38), resulting in the activation of NFκB and cell survival [72] . It has been shown that activation of the MAPK pathway may cause stimulation of phase II detoxifying enzymes while inhibition of MAPK pathways may suppress AP-1-mediated gene expression causing inactivation of NFκB [73] . Genistein, a recognized tyrosine kinase inhibitor, probably could inhibit this enzyme upstream of p38 MAPK and then suppress the phosphorylation of tyrosine on p38 MAPK, resulting in inactivation of the MAPK pathway.
The activity of genistein against colon carcinoma has also been reported by preventing proliferation of HCT116 colon carcinoma cells by stopping the G2/M phase. Genistein has also shown an effect on DNA topoisomerase II [74] .
In a recent study by Parra et al., genistein was found to inhibit cell growth of HER2-type MDA-MB-435 cells, as well as basal-type Hs578t cancer cells, although it was effective on MCF-7 cells only at higher concentrations (50 μM) [58] .
Metabolism: Isoflavones are mostly available as glycosides, which, upon ingestion, break to liberate the free aglycone by a βglucosidase enzyme i.e. deglycosylation. Deglycosylation starts in the mouth and continues in the small intestine where, after absorption, the aglycones undergo phase 1 and phase 2 metabolism in the liver.
Phase 1 metabolism
Reduction: Phase 1 metabolism mainly occurs through the reduction pathway. That of daidzein and genistein has been studied to a great extent. A comprehensive study on soy isoflavone metabolism was carried out by Kelly et al. in 1993 [75, 76] . They reported equol, dihydrodaidzein and o-desmethylangolensin (O-dma) as major metabolites of daidzein.
The major metabolites of genistein were dihydrogenistein and 6'-OH-O-dma, identified in urine samples after soy supplementation.
Demethylation: Isoflavones containing methoxy groups are demethylated. Glycitein also undergo demethylation, but to a lesser extent [77] .
Hydroxylation: Roberts-Kirchhoff et al. studied the oxidative metabolism of genistein by rat and human cytochrome P450s [78] and identified five metabolites, which included orobol, 3',4', 5, 7tetrahydroxyisoflavone, two metabolites having a hydroxyl group at the 6 and 8 positions, and two yet to be identified.
In vitro metabolism of dietary daidzein and genistein by Aroclorinduced rat liver microsomes has also been reported. Nine
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Natural Product Communications Vol. 12 (4) 2017 631 hydroxylated metabolites were identified for daidzein and six for genistein in an NADPH dependent reaction. The study indicated that daidzein and genistein are excellent substrates for cytochrome P450 enzymes. The monohydroxylated metabolites are further metabolized by cytochrome P450 to di-and tri-hydroxylated metabolites [79] .
Methylation: In a study by Kulling et al., the four in vivo metabolites were tentatively identified (3′-or 4′-methyl-7,3′,4′trihydroxyisoflavone, one dimethylated and two monomethylated catechols). Each of the methylated catechols was found only in very small amounts suggesting that methylation by catechol-O-methyl transferase (COMT) does not play a major role in the biotransformation of isoflavones in vivo [80] .
Phase II metabolism:
Several studies show that isoflavones are present as glucuronides i.e. 7-glucuronide followed by 4-glucuronides, and small proportions of sulfate esters are also found [81, 82] . Hosoda et al. used an HPLC-UV-DAD method with solid-phase extraction to directly measure the isoflavone glycosides and metabolites such as glucuronides and sulfates after intake of soyabean flour [83] .
Bioavailability: Bioavailability is a measure of the extent of these potential molecules that is available for vital biological effects. Therefore, a thorough understanding of bioavailability plays a key role in evaluating the potential health benefits of isoflavones and may assist in the interpretation of the high variability of results in clinical trials. The pharmacokinetics of absorption, distribution, metabolism, and elimination all contribute to the bioavailability, which further contributes to the effectiveness of isoflavones [84] . Only plasma and urinary measurements of isoflavones differentiate between the contributions of the intestine, liver, and other organs in isoflavones metabolism [85] . The isoflavones in soy are not biologically active unless they are digested and absorbed in the small intestine. Enzymes in the small intestine convert the isoflavone molecules by removing the glycosidic portion from them turning them into bioactive forms.
Even though studies have demonstrated the positive influence of isoflavones on human health, the clinical application of isoflavones is delayed due to poor aqueous solubility and low serum levels after oral administration [86] .
Setchell et al. determined the bioavailability of naturally occurring isoflavones in healthy adults [87] . The difference in pharmacokinetic behavior of isoflavone glycosides was compared with their respective β-glycosides. From the study it was found that the t max of daidzein and genistein was less for aglycones i.e. 6.6 and 5.2 h, respectively, while for β-glycosides it was higher i.e. 9.0 and 9.3h, respectively, indicating that the initial hydrolysis of the glycoside limited the absorption of these isoflavones. By carrying out studies on pure isoflavones it was found that genistein was more bioavailable than daidzein. The mean maximum plasma concentration of daidzein (Cmax) was 194 ± 30.6 ng/mL (0.76 ± 0.12 mmol/L), while for genistein, it was 341 ± 74 ng/mL (1.26 ± 0.27 mmol/L) [88] , whereas in another study by Xu et al., daidzein in soy milk was found to be more bioavailable than genistein in adult women [89] . It is also concluded that conjugates of daidzein are more bioavailable than those of genistein, probably because of the greater resistance of the former to degradation by gut bacteria [90] .
As reported by Setchell et al., the systemic bioavailability was found to be more for β-glycosides than their aglycones as determined by comparing dose normalized AUCs (2.94 ± 0.22 mg/(mL.h), 4.54 ± 1.41 mg/(mL.h) for daidzein and genistein, respectively. The AUC was found to be 4.52 ± 0.49 mg/ (mL.h), 4.95 ± 1.03 mg/(mL.h) for daidzin and genistin, respectively. On the contrary, Izumi et al. reported that isoflavone aglycones were more bioavailable than their glycosides [91] . Thus bioavailabilty of isoflavones is still controversial and needs to be explored exhaustively. Cassidy et al. studied the effect of gender, age and food matrix on the bioavailability of isoflavones for both aglycones and glycosides that are naturally present in three different soy foods, soy milk, textured vegetable protein (TVP)-a soy product, and tempeh (a fermented soy product). The study population involved premenopausal women, post-menopausal women and men. In the soy milk fed group, the AUC (0-t) was higher for genistein and daidzein than in the TVP fed group. In the case of daidzein, postmenopausal women had more bioavailability, as found by a significant difference in the AUC (0-t) (P = 0.0283), whereas no such age related differences were found with genistein. TVP mainly contains isoflavones glycosides whereas tempeh contains primarily aglycones. The study concluded that there was a significant increase in C max after the ingestion of tempeh compared with TVP for both genistein and daidzein. In the case of tempeh intake, the AUC (0-t) of total daidzein in serum increased by 20-120% (P < 0.0001) and also the AUC (0-t) for serum total genistein increased (P= 0.0217) compared with TVP intake [92] .
In a study by Chang et al., the plasma concentration of daidzein in soy products containing a high aglycone content was found to be higher than those with less aglycone content [93] .
The bioavailability of isoflavones varies widely and remains a subject for further research. The bioavailability of isoflavones varies greatly depending on their presence in different dietary sources; this could be valuable data for the design and interpretation of intervention studies exploring the health effects of these potential phytochemicals.
Conclusion:
The reported therapeutic effects of isoflavones require their adequate delivery from the site of administration to the site of action. The bioavailability of isoflavones is the major factor determining their biological action, which in turn depends upon solubility, partition coefficient, permeability, distribution, metabolism, target tissue uptake, and excretion of these potential molecules, with solubility being the major determinant as they belong to BCS class 2. Various approaches have been documented by researchers including complexation with cyclodextrins, micro emulsion, nanoparticles, and spray-dried soy isoflavone loaded gelatin, which has been used for improving its solubility and consequently its bioavailability. Co-crystallization is a recent green chemistry approach and is efficiently used for the enhancement of solubility. Genistein co-crystallized with isonicotinamide, nicotinamide and caffeine have recently been reported. No cocrystals of other isoflavones have been reported as yet. Overall the picture is very bright for the use of isoflavones in the treatment of chronic diseases and additional exploration is certainly required by scientific and medical communities for the development of effective and more bioavailable form of these isoflavones.
